Related Experiment Videos
Cellular and functional defects in a mouse model of heart failure
G Esposito1, L F Santana, K Dilly
1Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.
American Journal of Physiology. Heart and Circulatory Physiology
|November 22, 2000
Summary
Mice lacking muscle LIM protein (MLP) develop heart failure. Blocking beta-adrenergic receptor kinase-1 (betaARK1) restored heart function, suggesting betaARK1 inhibition as a potential heart failure therapy.
Area of Science:
- Cardiology
- Molecular Biology
- Physiology
Background:
- Mice lacking the muscle LIM protein (MLP) gene exhibit heart failure and dilated cardiomyopathy.
- Understanding the mechanisms of heart failure in MLP-deficient mice is crucial for developing therapeutic strategies.
Purpose of the Study:
- To investigate the characteristics of heart failure in MLP(-/-) mice.
- To elucidate the cellular mechanisms underlying heart dysfunction in MLP(-/-) mice.
- To explore the therapeutic potential of inhibiting beta-adrenergic receptor kinase-1 (betaARK1).
Main Methods:
- Echocardiography and in vivo pressure-volume (P-V) loop measurements using sonomicrometry.
- Patch-clamp and confocal Ca(2+) imaging techniques on isolated cardiac cells.
- Genetic manipulation using cardiac-targeted transgenes to block betaARK1 function.
Main Results:
- MLP(-/-) mice displayed right-shifted P-V loops, depressed systolic contractility, and cellular defects in excitation-contraction coupling.
- While Ca(2+) currents were unchanged, intracellular [Ca(2+)] transients and contractile responses were decreased.
- Restoration of normal cardiac function was observed in MLP(-/-) mice expressing a betaARK1-inhibiting transgene.
Conclusions:
- Downregulation and desensitization of beta-adrenergic receptors (beta-ARs) play a key role in the pathogenesis of heart failure in MLP(-/-) mice.
- Inhibition of betaARK1 activity represents a promising therapeutic approach for heart failure.